Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised Trial of Tenecteplase vs. Alteplase for Recanalisation in Acute Ischemic Stroke

Next Previous
Trial Profile

Randomised Trial of Tenecteplase vs. Alteplase for Recanalisation in Acute Ischemic Stroke

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenecteplase (Primary) ; Alteplase
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms NOR-TEST

    • Most Recent Events

    • 01 May 2019 Post Hoc analysis results (n=348) assessing the rates of favorable outcome at 90 days, symptomatic intracerebral hemorrhage (sICH), and mortality after 7 and 90 days between tenecteplase and alteplase are published in the Stroke
    • 03 Jan 2019 Results of prespecified substudy of NOR-TEST assessing efficacy and safety of tenecteplase and alteplase in patients treated 3 to 4.5 hours after ischemic stroke, published in the Stroke.
    • 19 Jun 2018 Results of post-hoc analysis presented at the 4th Congress of the European Academy of Neurology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top